Oncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US
Company News Oncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US Hørsholm, Denmark and Cambridge, MA, US, December 18, 2018 – Oncology Venture A/S (“OV” or the Company) today announced that the US …